Renal cell carcinoma (RCC) is the most common type of kidney or renal cancer, according to the American Cancer Society, with around 80-90% of the cancer cases reported being diagnosed as renal cell carcinoma. Transitional cell carcinoma (TCC) is another type of kidney cancer present among a few individuals (5% - 10% of the kidney cancer patients in the U.S.). At times, surgical treatment alone is not sufficient for treating RCC; if a person has developed metastatic cancer, he/she could be recommended for additional treatment regimens. Targeted therapies or immunotherapies are the most commonly prescribed treatments for kidney cancer. Targeted therapies are known to act at the cellular level, hence their accuracy and effectiveness increases with reduced toxicity. Therefore, kidney cancer drugs are among the only life-prolonging treatment regimens available for patients with advanced stage metastatic tumor.
The global kidney cancer drugs market is expected to grow at a stable growth rate during the forecast period, due to various factors such as increasing geriatric population and rising incidence of kidney cancer as well as approval of novel drug molecules. However, few factors that are expected to negatively affect the growth of the market are increasing preference for generic drug variants and high prices of branded cancer drugs.
The global kidney cancer drugs market has been segmented based on major branded drugs and geography. Based on prominent brands of drugs, the kidney cancer drugs market is divided into: Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin/Interleukin-2), Sutent (Sunitinib), Torisel (Temsirolimus), and Votrient (Pazopanib). In terms of revenue, Sutent was the largest-selling kidney cancer drug in 2013. This is because Sutent is the most commonly prescribed drug in the first-line treatment against kidney cancer and is among the most studied drugs in its class for multiple indications, as it targets multiple receptor tyrosine kinases (RTKs). In February 2006, the U.S. FDA approved Sunitinib for two indications, namely, RCC and gastrointestinal stromal tumor (GIST), making it the first cancer drug to receive approval in the U.S. However, GSK’s Votrient is expected become the market leader by 2017 surpassing Sutent and other competitors due to low pricing and superior first-line penetration, displaying the fastest growth rate at CAGR of over 40% from 2012 to 2016 and over 5% from 2016 to 2020. The market growth of Votrient is supported by the fact that during Phase III comparison trials, the drug showed better patient compatibility and safety profile with lower side effects as compared with interferon, placebo and other targeted therapies.
North America is the largest market for kidney cancer drugs due the commercial availability of major branded drugs for kidney cancer treatment and presence of large patient pool suffering from various forms of kidney cancer. North America dominated the market mainly due to the presence of a large patient population and the lucrative health care system tailor-made for the pharmaceutical industry. Exclusive patent rights and presence of a large health care insurance base have driven the pharmaceutical market in the U.S., thereby making North America the market leader for kidney cancer drugs. Asia Pacific is expected to observe an admirable growth due to multiple factors such as rising incidence of renal cell carcinoma, growing geriatric population and rapid economic development in nations such as India, China, Singapore, Malaysia and others, that contribute to the growth of kidney cancer drugs market in the region.
At present, the market is highly consolidated and aggressive in nature due to the presence of biggest pharmaceutical giants such as Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG and Pfizer, Inc. Among these, Pfizer, Inc. grabbed the largest share of the global kidney cancer drugs market in 2013. Since, Sutent (Sunitinib) and Inlyta (Axitinib) are the leading drugs for the treatment of kidney cancer, the global market of kidney cancer drugs is ruled by one of the world’s largest biopharmaceutical companies, Pfizer, Inc. However, other established market players such as Novartis and GSK are focusing on expanding their geographical presence as well as distribution network in emerging nations, since Asia Pacific, Latin America and the Middle East are developing regions with an increasing incidence rate of various forms of kidney cancer and improving economic conditions.
Kidneys are among the most crucial organs of the human body. Their role in regulating blood pressure and serving homeostatic functions is critical in maintaining the balance of nutrients and toxins in the body. Kidneys serve as natural blood filters, removing the water-soluble wastes and reabsorbing the essential elements from the blood. Since they play such a crucial role, kidneys require constant regeneration of dead nephrons and proper blood circulation to maintain healthy cell growth, due to which, they are susceptible to metastasis and cancerous tumors. Renal cell carcinoma, the most common type of kidney cancer, is among the toughest cancers to treat, especially in the advanced stages. Until 1980’s, the treatment of kidney cancer included surgical removal of the kidneys. The treatment later progressed to laparoscopic removal of the tumor-affected part of the kidneys, significantly increasing the survival rate and patient comfort. Drugs are usually given to stage four advanced renal cell carcinoma patients with disease progression. Various forms of cancer treatment mechanism have been implemented among the presently approved drugs for kidney cancer; these include, VEGF (Vascular Endothelial Growth Factor) inhibitor, angiogenesis inhibitor, cytokine therapy, and immune modulation therapy to name a few.
This research report provides a detailed analysis of the global kidney cancer drugs market and helps in understanding the various driving factors of this market. The market overview section provides analysis of the market dynamics and trends such as drivers, restraints, and opportunities that influence the current nature of the market. The section also forecasts the future scenario of the market. The executive summary gives detailed insights about the report and the market in general. It also contains a market snapshot, which provides a glimpse into the current scenario of the global kidney cancer drugs market. Event impact analysis and other market dynamics tools such as market attractiveness analysis, regulatory framework analysis, and market share analysis have also been explained in the market overview section of the report, in order to deliver a thorough analysis of the overall competitive scenario in the global kidney cancer drugs market.
The global kidney cancer drugs market is segmented on the basis of major branded drugs produced and geography. By major branded drugs, the market is further segmented into the major brands approved for the indication of renal cell carcinoma such as Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin/Interleukin-2), Sutent (Sunitinib), Torisel (Temsirolimus), and Votrient (Pazopanib). The report also includes pipeline analysis of the most potential drugs, which are currently in phase 2 and phase 3 trials for renal cell carcinoma indication. Considering 2013 as the base year for estimating the market size and 2012 as the historical year, the market size estimations for the period from 2012 to 2020 have been provided for each of the major branded drugs mentioned above in terms of USD million. The CAGR (%) of each market segment for the forecast period between 2012 to 2016 and 2016 to 2020 has also been provided along with market size estimations.
Geographically, the global kidney cancer drugs market has been segmented into four major regions: North America, Europe, Asia Pacific, and Rest of World (RoW), Russia being included in the RoW region. The market size estimations for the period between 2012 and 2020 and market forecast for the period 2014 - 2020 have been provided for each of these regions by revenue in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for market players of the global kidney cancer drugs market, which include factors that may play a critical role in enhancing or boosting the market share of companies in the near future. The report also advices measures that need to be considered to achieve success for kidney cancer drug manufacturers and marketers globally.
The report concludes with company profiles, which include key information about the major players actively participating in the kidney cancer drugs market. The report profiles the market players in terms of company overview, financial overview, business strategy, recent developments, and product portfolio. The companies featured in this report have exclusive patent rights to the following major branded drugs: Novartis AG., F. Hoffman-La Roche., Pfizer, Inc., Bayer Pharma AG., and GlaxoSmithKline, plc.
The global kidney cancer drugs market is segmented as follows:
Kidney Cancer Drugs Market, by Major Branded Drugs
- Sutent (Sunitinib)
- Nexavar (Sorafenib)
- Afinitor (Everolimus)
- Votrient (Pazopanib)
- Inlyta (Axitinib)
- Avastin (Bevacizumab)
- Torisel (Temsirolimus)
- Proleukin (Aldesleukin)
Kidney Cancer Drugs Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)